Article (Scientific journals)
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.
Ludwig, Heinz; Sonneveld, Pieter; Facon, Thierry et al.
2021In The Lancet Haematology, 8, p. 934-e946
Peer Reviewed verified by ORBi
 

Files


Full Text
COVID-19 vaccination in patients with multiple myeloma a consensus of the European Myeloma Network.pdf
Author postprint (376.2 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for infections and infection-related mortality. The risk for infection with SARS-CoV-2 virus and resulting mortality is also increased, emphasising the importance of protecting patients by vaccination. Available data in patients with multiple myeloma suggest a suboptimal anti-SARS-CoV-2 immune response, meaning a proportion of patients are unprotected. Factors associated with poor response are uncontrolled disease, immunosuppression, concomitant therapy, more lines of therapy, and CD38 antibody-directed and B-cell maturation antigen-directed therapy. These facts suggest that monitoring the immune response to vaccination in patients with multiple myeloma might provide guidance for clinical management, such as administration of additional doses of the same or another vaccine, or even temporary treatment discontinuation, if possible. In those who do not exhibit a good response, prophylactic treatment with neutralising monoclonal antibody cocktails might be considered. In patients deficient of a SARS-CoV-2 immune response, adherence to measures for infection risk reduction is particularly recommended. This consensus was generated by members of the European Multiple Myeloma Network and some external experts. The panel members convened in virtual meetings and conducted an extensive literature research and evaluated recently published data and work presented at meetings, as well as findings from their own studies. The outcome of the discussions on establishing consensus recommendations for COVID-19 vaccination in patients with multiple myeloma was condensed into this Review.
Precision for document type :
Review article
Disciplines :
Hematology
Author, co-author :
Ludwig, Heinz
Sonneveld, Pieter
Facon, Thierry
San-Miguel, Jesus
Avet-Loiseau, Hervé
Mohty, Mohamad
Mateos, Maria-Victoria
Moreau, Philippe
Cavo, Michele
Pawlyn, Charlotte
Zweegman, Sonja
Engelhardt, Monika
Driessen, Christoph
Cook, Gordon
Dimopoulos, Melitios A.
Gay, Francesca
Einsele, Hermann
Delforge, Michel
Caers, Jo  ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Weisel, Katja
Jackson, Graham
Garderet, Laurent
van de Donk, Niels
Leleu, Xavier
Goldschmidt, Hartmut
Beksac, Meral
Nijhof, Inger
Schreder, Martin
Abildgaard, Niels
Hajek, Roman
Zojer, Niklas
Kastritis, Efstathios
Broijl, Annemiek
Schjesvold, Fredrik
Boccadoro, Mario
Terpos, Evangelos
More authors (26 more) Less
Language :
English
Title :
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.
Publication date :
2021
Journal title :
The Lancet Haematology
eISSN :
2352-3026
Publisher :
Elsevier, United Kingdom
Volume :
8
Pages :
e934-e946
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Crown Copyright © 2021 Published by Elsevier Ltd. All rights reserved.
Available on ORBi :
since 11 November 2021

Statistics


Number of views
97 (6 by ULiège)
Number of downloads
54 (6 by ULiège)

Scopus citations®
 
40
Scopus citations®
without self-citations
25
OpenCitations
 
13

Bibliography


Similar publications



Contact ORBi